Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

heart failure

26th Nov 2025

Plain language summary: real-world tafamidis study in transthyretin amyloid cardiomyopathy (ATTR-CM) patients

20th Jun 2025

Plain language summary: how aficamten performed in the SEQUOIA-HCM trial for patients with symptomatic obstructive hypertrophic cardiomyopathy

27th May 2025

How tafamidis affects lifespan in people with transthyretin amyloid heart disease: plain language summary

20th May 2025

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary

23rd Sep 2024

Impact of extended tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM)

The EMPEROR-Preserved study looked at the effects of empagliflozin in participants with heart failure with a preserved ejection fraction (HFpEF). This is when the lower left part of the heart (left ventricle) squeezes normally or near normally but does not fill with enough blood between heartbeats. Therefore, not enough blood is pumped around the body. For this study, HFpEF was defined as a condition in which more than 40% of blood in the left ventricle was pumped around the body.
22nd Jan 2024

The effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes: a plain language summary

his summary describes a study of a new pill for treating chronic heart failure called empagliflozin (brand name Jardiance®). The study is called EMPEROR-Preserved and was published in the New England Journal of Medicine. Chronic heart failure is a condition where the heart does not pump blood around the body properly. Heart failure causes symptoms such as shortness of breath, tiredness and build-up of too much water in the body (fluid retention). These symptoms often need hospital treatment and increase the risk of early death
16th Nov 2023

Plain language summary of the EMPEROR-Preserved : drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction

This is a summary of the article describing the EMPEROR-Reduced study of empagliflozin, which was published in the New England Journal of Medicine. Empagliflozin (brand name Jardiance®) is a new drug therapy for the treatment of chronic heart failure. Chronic heart failure is a long-term condition where the heart cannot pump enough blood around the body, leading to symptoms such as shortness of breath, fatigue and build-up of too much water in the body (fluid retention). It also increases the risk for premature death
15th Nov 2023

A plain language summary of the EMPEROR-Reduced study: drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction

11th Apr 2023

Plain Language Summary: long-term survival in people being treated with tafamidis for transthyretin amyloid cardiomyopathy

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy